Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 4242

1.

Update on multikinase inhibitor therapy for differentiated thyroid cancer.

Agrawal VR, Jodon G, Mushtaq R, Bowles DW.

Drugs Today (Barc). 2018 Sep;54(9):535-545. doi: 10.1358/dot.2018.54.9.2878150.

PMID:
30303494
2.

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.

Del Rivero J, Edgerly M, Ward J, Madan RA, Balasubramaniam S, Fojo T, Gramza AW.

Oncologist. 2018 Oct 8. pii: theoncologist.2018-0452. doi: 10.1634/theoncologist.2018-0452. [Epub ahead of print]

PMID:
30297385
3.

Therapeutic Activity of DCC-2036, a Novel Tyrosine Kinase Inhibitor, against Triple-Negative Breast Cancer Patient-Derived Xenografts by Targeting AXL/MET.

Shen Y, Zhang W, Liu J, He J, Cao R, Chen X, Peng X, Xu H, Zhao Q, Zhong J, Ding W, Lei X, Jiang Y, Zu X.

Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31915. [Epub ahead of print]

PMID:
30289981
4.

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.

Kim SY, Kim SM, Chang HJ, Kim BW, Lee YS, Park CS, Park KC, Chang HS.

BMC Cancer. 2018 Oct 4;18(1):956. doi: 10.1186/s12885-018-4854-z.

5.

Gene expression differences between thyroid carcinoma, thyroid adenoma and normal thyroid tissue.

Wang Q, Shen Y, Ye B, Hu H, Fan C, Wang T, Zheng Y, Lv J, Ma Y, Xiang M.

Oncol Rep. 2018 Sep 20. doi: 10.3892/or.2018.6717. [Epub ahead of print]

PMID:
30272326
6.

Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress.

Wang G, Zhuang J, Ni J, Ye Y, He S, Xia W.

Exp Ther Med. 2018 Oct;16(4):3325-3332. doi: 10.3892/etm.2018.6652. Epub 2018 Aug 23.

7.

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.

Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J.

J Hematol Oncol. 2018 Sep 19;11(1):120. doi: 10.1186/s13045-018-0664-7. Review.

8.

Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.

Mahajan P, Dawrant J, Kheradpour A, Quintanilla NM, Lopez ME, Orth RC, Athanassaki I, Venkatramani R.

Thyroid. 2018 Oct 16. doi: 10.1089/thy.2018.0064. [Epub ahead of print]

PMID:
30226445
9.

[A Case of Carcinoma Showing Thymus-Like Differentiation (CASTLE) of the Thyroid].

Inoue Y, Kohi S, Gobara M, Joden F, Yabuki K, Tanoue T, Sato N, Katsuki T, Nagata T, Shibao K, Hisaoka M, Hirata K.

J UOEH. 2018;40(3):259-266. doi: 10.7888/juoeh.40.259. Japanese.

10.

A mono-carbonyl analog of curcumin induces apoptosis in drug-resistant EGFR-mutant lung cancer through the generation of oxidative stress and mitochondrial dysfunction.

Dai X, Zhang J, Guo G, Cai Y, Cui R, Yin C, Liu W, Vinothkumar R, Zhang T, Liang G, Zhang X.

Cancer Manag Res. 2018 Aug 29;10:3069-3082. doi: 10.2147/CMAR.S159660. eCollection 2018.

11.

Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib.

Werner RA, Bundschuh RA, Higuchi T, Javadi MS, Rowe SP, Zsótér N, Kroiss M, Fassnacht M, Buck AK, Kreissl MC, Lapa C.

Endocrine. 2018 Sep 11. doi: 10.1007/s12020-018-1749-3. [Epub ahead of print]

PMID:
30206772
12.

Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.

Gosain R, Alexander JS, Gill A, Perez C.

Curr Oncol Rep. 2018 Sep 11;20(10):82. doi: 10.1007/s11912-018-0736-4. Review.

PMID:
30206719
13.

Current treatment strategies in metastasized differentiated thyroid cancer.

Kreissl M, Janssen M, Nagarajah J.

J Nucl Med. 2018 Sep 6. pii: jnumed.117.190819. doi: 10.2967/jnumed.117.190819. [Epub ahead of print]

PMID:
30190306
14.

Molecular characterization of cancers with NTRK gene fusions.

Gatalica Z, Xiu J, Swensen J, Vranic S.

Mod Pathol. 2018 Aug 31. doi: 10.1038/s41379-018-0118-3. [Epub ahead of print]

PMID:
30171197
15.

Difference in control between spring and autumn migration in birds: insight from seasonal changes in hypothalamic gene expression in captive buntings.

Sharma A, Singh D, Malik S, Gupta NJ, Rani S, Kumar V.

Proc Biol Sci. 2018 Aug 29;285(1885). pii: 20181531. doi: 10.1098/rspb.2018.1531.

PMID:
30158302
16.

Physiology, Thyroid.

Pirahanchi Y, Jialal I.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Sep 12.

17.

Overexpression of the Thyroid Hormone-Responsive (THRSP) Gene in the Striatum Leads to the Development of Inattentive-like Phenotype in Mice.

Custodio RJP, Botanas CJ, de la Peña JB, Dela Peña IJ, Kim M, Sayson LV, Abiero A, Ryoo ZY, Kim BN, Kim HJ, Cheong JH.

Neuroscience. 2018 Oct 15;390:141-150. doi: 10.1016/j.neuroscience.2018.08.008. Epub 2018 Aug 21.

PMID:
30138648
18.

Evaluating iodide recycling inhibition as a novel molecular initiating event for thyroid axis disruption in amphibians.

Olker JH, Haselman JT, Kosian PA, Donnay KG, Korte JJ, Blanksma C, Hornung MW, Degitz SJ.

Toxicol Sci. 2018 Aug 20. doi: 10.1093/toxsci/kfy203. [Epub ahead of print]

PMID:
30137636
19.

Contributions of Thyroid Hormone to Cancer Metastasis.

Mousa SA, Glinsky GV, Lin HY, Ashur-Fabian O, Hercbergs A, Keating KA, Davis PJ.

Biomedicines. 2018 Aug 22;6(3). pii: E89. doi: 10.3390/biomedicines6030089. Review.

20.

EphB2 Deficiency Induces Depression-Like Behaviors and Memory Impairment: Involvement of NMDA 2B Receptor Dependent Signaling.

Zhen L, Shao T, Luria V, Li G, Li Z, Xu Y, Zhao X.

Front Pharmacol. 2018 Aug 7;9:862. doi: 10.3389/fphar.2018.00862. eCollection 2018.

Supplemental Content

Loading ...
Support Center